Effective Date of Requirement for Premarket Approval Applications for Blood Irradiators Intended To Prevent Metastasis

The commenter supports the proposed action but argues for stricter requirements, including a shorter compliance window, mandated clinical trial diversity, and specific requirements for in vivo clinical endpoints and post-irradiation analysis. They also advocate for distinct product codes for metastasis-prevention devices and a transition away from radioactive isotopes.